Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 20/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 20/20 | 0.49 |
| ▸ | LYN | P07948 | 11/20 | 0.48 |
| ▸ | PRKCB | P05771 | 3/20 | 0.46 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.46 |
| ▸ | LCK | P06239 | 3/20 | 0.46 |
| ▸ | PRKCH | P24723 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5529400 | 0.83 | PRKCQ (0.46) | PRKCQPRKCDLYNPRKCBPRKCE | |
| SCHEMBL4953039 | 0.82 | PRKCQ (0.75) | PRKCQPRKCDLYNPRKCBPRKCE | |
| SCHEMBL5518368 | 0.81 | PRKCQ (0.51) | PRKCQPRKCDLYNPRKCBPRKCE | |
| SCHEMBL5529468 | 0.79 | PRKCQ (0.52) | PRKCQPRKCDLYNPRKCBPRKCE | |
| SCHEMBL5520498 | 0.77 | PRKCQ (0.53) | PRKCQPRKCDLYNPRKCBPRKCE | |
| SCHEMBL5522336 | 0.76 | PRKCQ (0.47) | PRKCQPRKCDLYNPRKCBPRKCE | |
| SCHEMBL5518731 | 0.76 | PRKCQ (0.47) | PRKCQPRKCDLYNPRKCBPRKCE | |
| SCHEMBL5517163 | 0.76 | PRKCQ (0.48) | PRKCQPRKCDLYNPRKCBPRKCE | |
| SCHEMBL5522368 | 0.75 | PRKCQ (0.44) | PRKCQPRKCDLYNPRKCBPRKCE | |
| SCHEMBL5532003 | 0.75 | PRKCQ (0.55) | PRKCQPRKCDLYNPRKCBPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082880-A1 | Thieno [2,3-B] pyridine-5-carbonitriles as protein kinase inhibitors | WYETH | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082880-A1 | Thieno [2,3-B] pyridine-5-carbonitriles as protein kinase inhibitors | MAP4K2, CNKSR1, MAP3K1 | PRKCQ 286/4885PRKCD 356/4885LYN 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.